A concern with chronic PAT1 inhibition is the hyperoxaluria and calcium oxalate nephrolithiasis seen in PAT1-knockout mice due to impaired intestinal oxalate secretion (23); however, SLC26A6 variants in humans are not associated with hyperoxaluria or nephrolithiasis (24). Here, SLC26A6 is linked to nephrolithiasis, calcium oxalate.